A Phase 3, Randomized, Open-label, Multicenter Study Comparing Ponatinib Versus Imatinib, Administered in Combination with Reduced-Intensity Chemotherapy, in Patients with Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
MD Anderson Study Status
Ponatinib, Imatinib, Vincristine, Dexamethasone, Cytarabine, Methotrexate, Prednisone
The purpose of this study is to compare the efficacy of ponatinib versus imatinib, administered as first-line therapy in combination with reduced-intensity chemotherapy, in participants with newly diagnosed Ph+ ALL, as measured by the minimal residual disease (MRD)-negative complete remission (CR) at the end of induction.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Lymphoblastic Leukemia, Acute, Adult, Acute Lymphoid Leukemia, Leukemia, Acute Lymphoblastic, Leukemia, Lymphoblastic, Ph1 Chromosome, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive
For general questions about clinical trials:
Help us #endcancer
Due to our response to COVID-19, all blood donations at MD Anderson
Blood Donor Center locations are being held by appointment only.